Splitting high-dose insulin, injecting in two sites improved blood glucose control

Fisher, Stacey L.; Kalvaitis, Katie
November 2011
Endocrine Today;Nov2011, Vol. 9 Issue 11, p24
The article focuses on a study which concluded that dividing high-dose insulin and injecting it in two sites can improve glycemic control in severely insulin-resistant patients with type 2 diabetes.


Related Articles

  • The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily. MENEGHINI, LUIGI; ATKIN, STEPHEN L.; GOUGH, STEPHEN C. L.; RAZ, ITAMAR; BLONDE, LAWRENCE; SHESTAKOVA, MARINA; BAIN, STEPHEN; JOHANSEN, THUE; BEGTRUP, KAMILLA; BIRKELAND, KÅRE I. // Diabetes Care;Apr20123, Vol. 36 Issue 4, p858 

    OBJECTIVE--The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy and safety of varying the daily injection time of insulin degludec (IDeg), an ultra-long-acting basal insulin....

  • Biodel Latest to Suffer a Complete Response Letter. Shaffer, Catherine // BioWorld Today;11/2/2010, Vol. 21 Issue 212, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) sent a complete response letter to Biodel Inc. in November 2010 about its Linjet human insulin injection to Type I and II diabetes. According to the letter, the company was able to establish the efficacy of the drug. Two new...

  • Glimepiride.  // AHFS Consumer Medication Information;Aug2020, p1 

    Glimepiride is used along with diet and exercise, and sometimes with other medications, to treat type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood). Glimepiride lowers blood sugar by causing the pancreas to...

  • A Feasibility Study of a 3-Day Basal-Bolus Insulin Delivery Device in Individuals With Type 2 Diabetes. Mader, Julia K.; Lilly, Leslie C.; Aberer, Felix; Korsatko, Stefan; Strock, Ellie; Mazze, Roger S.; Damsbo, Peter; Pieber, Thomas R. // Diabetes Care;May2014, Vol. 37 Issue 5, p1476 

    OBJECTIVE This study tested the feasibility of transition from multiple daily injections (MDI) to a 3-day, basal-bolus insulin delivery device (PaQ) for type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Twenty MDI-treated individuals with T2D with HbA1c ≤9% (75 mmol/mol) were enrolled in...

  • Insulin plus a sulfonylurea agent for treating type 2 diabetes. Peters, Anne L.; Peters, A L; Davidson, M B // Annals of Internal Medicine;7/1/91, Vol. 115 Issue 1, p45 

    Purpose: To review the recent literature on the efficacy of combined insulin and sulfonylurea therapy in patients with type 2 diabetes.Data Sources: Pertinent articles were obtained through an English-language MEDLINE search from 1979 to 1990 and from the references of...

  • Effect of pinitol treatment on insulin action in subjects with insulin resistance. Davis, Ajuah; Christiansen, Mark; Horowitz, Jeffrey F.; Klein, Samuel; Hellerstein, Marc K.; Ostlund JR., Richard E.; Davis, A; Christiansen, M; Horowitz, J F; Klein, S; Hellerstein, M K; Ostlund, R E Jr // Diabetes Care;Jul2000, Vol. 23 Issue 7, p1000 

    Objective: Endogenous low-molecular-weight glycans containing pinitol (3-O-methyl-D-chiro-inositol) and D-chiro-inositol are thought to mediate certain actions of insulin. We tested the hypothesis that oral administration of soybean-derived pinitol would improve insulin sensitivity...

  • Post-test.  // Drug Topics;12/11/2006, Vol. 150 Issue 23, special section p15 

    A series of test questions relating to the topic on insulin therapy for patients with type 2 diabetes is presented.

  • 4-T Trial: Outcomes better with oral therapy plus basal, prandial insulin vs. biphasic insulin. Southall, Jennifer // Endocrine Today;Nov2009, Vol. 7 Issue 13, p1 

    This article discusses a trial which compared the addition of basal or prandial insulin to oral therapy and a biphasic insulin-based regimen in patients with type 2 diabetes.

  • Rosiglitazone in type 2 diabetes. DiLoreto, Stacy; Roantree, Rosie // Patient Care for the Nurse Practitioner;Oct2001, Vol. 4 Issue 10, p50 

    Reports on a randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Patients and methods; Reduction in insulin.

  • S32 - THE EFFECT OF INSULIN ANALOG THERAPY ON REVERS CHOLESTEROL TRANSPORT AND LDL SUBFRACTION PROFILE IN TYPE 2 DIABETIC PATIENTS. DOĞAN, Serdar; ASLAN, İbrahim; KÜÇÜKSAYAN, Ertan; ASLAN, Mutay // Turkish Journal of Biochemistry / Turk Biyokimya Dergisi;2012 Special Issue, Vol. 37 Issue S1, p134 

    The aim of this study was to evaluate the effect of insulin analog initiation therapy on lipid metabolism and LDL subfractions in type 2 diabetic patients. Twenty four type 2 diabetic patients with HbA1c levels above 10% despite ongoing combination therapy with sulphonylurea and metformin were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics